GSK砸溢價62%併Tesaro 再度挺進癌症藥物領域 | 合法藥品大搜索

2018年12月4日 — TESARO成立於2010年，總部位於美國麻州沃爾瑟姆市(Waltham, Massachusetts)​，主要上市產品為Zejula（niraparib），是一種口服PARP（poly ... Read More

Our approach to R&D focuses on science related to the immune system, the use of human genetics and advanced technologies. · Tesaro created the following ... Read More

2019年1月22日 — TESARO is a commercial-stage biopharmaceutical company, with a major marketed product, Zejula (niraparib), an oral poly ADP ribose ... Read More

2018年12月3日 — TESARO is an oncology-focused biopharmaceutical company devoted to providing transformative therapies to people facing cancer. The ... Read More

2018年12月4日 — 在癌症治療公司Tesaro 於11 月所公布的T 细胞免疫球蛋白黏蛋白分子-3 （T-cell Ig​-mRead More. Read More

Tesaro is a pharmaceutical company based in Waltham, Massachusetts. They focus on drug development for cancer. Contents. 1 History; 2 Products under ... Read More

TESARO, Inc. | 26188 位LinkedIn 關注者。TESARO is an oncology-focused business within GlaxoSmithKline (GSK) with a clear mission that drives all of our​ ... Read More

TESARO is an oncology-focused business within GlaxoSmithKline (GSK) with a clear mission that drives all of our actions. We are dedicated to improving the ... Read More

2018年12月3日 — 葛蘭素史克GlaxoSmithKline GSK (GSK-LN) 週一(3 日) 同意以51 億美元收購藥廠Tesaro (TSRO-US) 後，股價自2008 年以來經歷了盤中交易中的 ... Read More